Dendreon Corp fka DNDNQ

[DewDiligence]

Any trial where overall survival is the primary endpoint is a counter to Ocyan’s argument.

Why would any sponsor ever take only one shot on goal—overall survival—if they could take two shots by exhausting 0.05 of p-value on some other endpoint (whether a surrogate or not) and then have another 0.05 of p-value for overall survival to boot?

The answer, of course, is that sponsors make overall survival a primary endpoint in many trials because they do not assume that the Coreg case is the norm.